Michael Krams, MD, joins Exscientia as Chief Quantitative Medicine Officer

Exscientia plc (Nasdaq: EXAI) today announced the appointment of Michael Krams, MD, as the Company’s Chief Quantitative Medicine Officer. In this newly created position, Dr. Krams to lead the clinical development strategy for Exscientia’s investigational drug portfolio. The Exscientia drug discovery platform uses patient-based translational models and AI-assisted molecular design to optimize drug candidates for specific patient populations. As part of this effort, Dr. Krams will advance initiatives to improve study design and patient selection for clinical trials to maximize clinical success and patient benefit.

“We aim to be as innovative in clinical research as we are in drug discovery. Mike is a seasoned innovator and has provided strategic leadership in bringing a quantitative scientific approach to clinical development. He has been a part of it for more than 20 years pioneered thought leaders in the field by introducing model-based drug development, expanding the use of biomarkers for adaptive studies, and exploring better ways to enrich studies for patient selection,” said Andrew Hopkins, DPhil., Founder and CEO of Exscientia. “By targeting our clinical trials to the people who will benefit most, we will not only improve clinical success rates, but also fulfill our mission to put patients at the center of new drug development.”

dr Krams will be a member of the executive team at Exscientia and will report to Andrew Hopkins. He will be based at Exscientia’s Center for Precision Medicine in Vienna, Austria. Most recently, Dr. Krams the Quantitative Sciences group at Janssen R&D, in which around 500 statisticians, pharmacologists and modelers work together to make decision-making in various areas of drug development more efficient. Previously, he was Vice President of Adaptive Trials and Applied Program Strategies at Wyeth. dr Krams holds an MD from the University of Munich.

“I look forward to my responsibilities at Exscientia – a company using artificial intelligence to transform drug discovery and development and create better medicines for patients. In many ways, the work I’ve dedicated to throughout my career aligns well with the Exscientia’s focus: How to further improve traditional, sequential approaches in clinical development to achieve truly patient-centric drug development Drug discovery and clinical strategies need to be closely linked through biomarker strategies, and Exscientia’s precision medicine platform has the potential to do just that,” comments Dr. Mike Krams, Chief Quantitative Medicine Officer at Exscientia.

About Exscientia

Exscientia is a pharmaceutical technology company dedicated to discovering, designing and developing the best possible drugs in the fastest and most effective way using AI. Exscientia has developed the first functional precision oncology platform that has successfully guided treatment choices and improved patient outcomes in a prospective clinical intervention study. She is also advancing small molecule compounds developed with the help of AI to clinical development. Our pipeline of more than 30 ongoing projects demonstrates our ability to rapidly translate scientific concepts into precise drug candidates. We believe that accelerating the development of more effective medicines will mean that the best ideas in science can be quickly translated into the best medicines for patients.

Exscientia is headquartered in Oxford (UK) and has offices in Vienna (Austria), Dundee (UK), Boston (Massachussetts, USA), Miami (Florida, USA), Cambridge (UK) and Osaka (Japan).

Visit us at https://www.exscientia.ai or follow us on Twitter @exscientiaAI.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding Exscientia’s expectations regarding its management team. Words such as “believe”, “believe”, “expect”, “intend”, “anticipate”, “anticipate” and “future” or similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to the uncertainties involved in predicting future results and conditions, and there can be no assurance that the drug discovery and precision medicine platforms described above will be successful in optimizing drug candidates for specific patient populations. The success of Exscientia’s platforms is subject to numerous factors, many of which are beyond Exscientia’s control. These include, but are not limited to, Exscientia’s ability to design FDA-approved clinical trials and healthcare providers’ ability to collect eligible tissue samples from patients. Exscientia undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

The source language in which the original text is published is the official and authorized version. Translations will be included for a better understanding. Only the language version that was originally published is legally valid. Therefore, compare translations with the original language version of the publication.

View original version on businesswire.com: https://www.businesswire.com/news/home/20220405005277/en/